After earning an MS Degree in Pharmacy, Dr Ahmann earned his medical degree at the University of Colorado School of Medicine. He completed an internal medicine internship and residency at Fitzsimons Army Medical Center, Denver, Colorado, and subsequently performed fellowships in both endocrinology and endocrinology research at Walter Reed Army Medical Center in Washington, DC.

A present member of the American Diabetes Association (ADA) National Professional Practice Committee, Dr Ahmann is also president of the ADA Portland Area Leadership Council. He served as the founding co-chair of the Oregon Diabetes Coalition and the chair of the Oregon Diabetes Collaborative. He serves as the chairman of the Oregon Diabetes Guidelines Committee. Dr. Ahmann was a member of the ADA Writing Committee for Inpatient Diabetes Management in 1993/94. He was also a Task Force member of the AACE for the Consensus Development Conference on Inpatient Diabetes and Metabolic Control in December 2003. Other relevant national activities include faculty participation in the ADA grand rounds program on “Insulin Therapy in the Hospital” and participation in the Glycemic Control Task Force of the Society of Hospital Medicine, developing a web-based comprehensive manual for guiding inpatient diabetes programs.

Carlos R. Hamilton, Jr., MD, FACE, has practiced clinical endocrinology and internal medicine, and he is the executive vice president of the University of Texas Health Science Center at Houston and a professor of internal medicine at the UT Houston Medical School. After graduating from Baylor College of Medicine, he completed his internship and residency at the Johns Hopkins Hospital, an endocrine fellowship at the Massachusetts General Hospital, and was chief resident in medicine at Hopkins. He was on the full-time faculty at Hopkins before serving two years as an endocrinologist at the Wilford Hall USAF Medical Center in San Antonio. He was in private practice for 26 years and was a clinical professor of medicine at Baylor College of Medicine before assuming his present position.

Dr. Hamilton has been active in medical organizations primarily as an advocate for medical practice and patient's rights. He has been a member of the AACE board of directors and served as chair of the AACE legislative and regulatory committee. He has also served as president of the Texas Society of Internal Medicine, the Harris County Medical Society and as chair of the Texas Medical Association Political Action Committee. He has served as a trustee of the American Society of Internal Medicine, as a member of the ACP-ASIM Health and Public Policy Committee and as a member of the AMA Federation Advisory Committee. He served as the 2004–2005 AACE president and as a trustee of the American College of Endocrinology. He is a past president on the AACE board of directors and president-elect of the American College of Endocrinology. He is a member of the practicing physicians advisory council to the US Secretary of Health and Human Services for issues related to the Center of Medicare and Medicaid Services. He also serves on the health, medicine and research committee of the World Anti-Doping Agency, which oversees the international prohibitions of the use of hormones and performance enhancing substances in athletic competition.

Dale J. Hamilton, M.D. is attending physician at the Methodist Academic Medical Associates and the clinical service chief of the division of diabetes, obesity and lipids at The Methodist Hospital, Houston, TX. He came to the TMH Department of Medicine from Baylor College of Medicine where he was Associate Professor of medicine and director to the Baylor Methodist diabetes management program. He is a member of the national organization and a council member of the Houston chapter of the American Diabetes Association. He is an active member of the American college of Physicians and a Fellow of American College of Endocrinologists.

Dr. Hamilton received his medical degree from St. Louis University in St. Louis, MO, and underwent medical residency at Baylor College of Medicine, Houston, TX. He completed post-residency fellowship training in diabetes and endocrinology at Baylor. He has held clinical and full-time faculty positions at BCM. At Baylor he lectured in pathophysiology to second-year medical students and in the therapeutics of diabetes to fourth year medical students. He was active in the endocrine fellowship training program where he developed a core reading curriculum for first-year fellows.

Dr. Hamilton has participated in research related to diabetes. He was a co-investigator in the islet transplant program for patients with type 1 diabetes and unstable control. He has collaborated in pharmaceutical trials evaluating anti-hypertensive agents and oral hypoglycemic medications in the treatment of patients with type 2 diabetes. His research interests have turned to the pathophysiology and metabolic management of patients with diabetes and heart disease. He now has a trial investigating methods to improve inpatient diabetes control after heart surgery. He co-authored with a cardiologist and cardiovascular surgeon and recently published a review of diabetes after heart transplantation.

Dr. Alan Garber graduated from Temple University, Philadelphia, in 1968, completed a PhD in Biochemistry in 1971, and a residency in Internal Medicine. Subsequently, he was a fellow in Metabolism and then a junior faculty member at Washington University Medical School and Barnes Hospital in St. Louis. In 1974, he transferred to Baylor College of Medicine in Houston, where he is presently a Professor in the Departments of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology.

In addition to a prior term as a member of the Board of Directors of the American Association of Clinical Endocrinologists (AACE), Dr. Garber has also served on the boards of other organizations, including the National Board of Directors of the American Diabetes Association, the Southern Section of the American Federation of Clinical Research and the Southern Society for Clinical Investigation. Elected positions include those of President of the Southern Society for Clinical Research, The Southern Society for Clinical Investigation, and the Texas Affiliate of the American Diabetes Association. Dr. Garber chaired the Writing Committee for the AACE/ACE Consensus Statement on Outpatient Guidelines for Glycemic Control (2002) and was the co-chair, as well as the chairman, of the Writing Committee for the Consensus Development Conference on Inpatient Diabetes and Metabolic Control (2003). Dr. Garber is a member of the ACE Diabetes Initiative Advisory Board and chairs task forces on diabetes prevention for ACE and AACE and the Coordination of Specialty Societies Monitoring the Appropriate Use of Pharmacological Agents. He was also the co-chair of the Organizing Committee for the 2005 AACE Annual Meeting in Washington, DC, and co-chair of the 2005 AACE Annual Meeting. Most recently, Dr. Garber co-chaired the AACE/ACE/ADA 2006 Inpatient Diabetes and Control: A Call to Action Consensus Conference and chaired the writing panel which produced the resulting Consensus Statement recommending strategies for improving patient care. Additional current memberships in AACE task forces include the Task Force for Endocrine Educational Services, the Inpatient Diabetes Management Implementation Consensus Conference Task Force to Communicate with JCAHO, the Task Force to Review the Endotext Proposal and the Optimal Diabetes Care Task Force.

Paul S. Jellinger, MD, MACE, is a Past President of the American Association of Clinical Endocrinologists (AACE) and a Past President of the American College of Endocrinology (ACE). He is a Professor of Medicine on the voluntary faculty at the University of Miami. In May 2004, he became a Master of the American College of Endocrinology (MACE).

After receiving his medical degree from Wayne State University School of Medicine, Dr. Jellinger completed a first-year medical residency at Beth Israel Hospital and a second-year residency at Mount Sinai Hospital in New York City. He subsequently was awarded an NIH fellowship in Endocrinology at Mount Sinai Hospital. Dr. Jellinger has served as Chief of the Section of Endocrinology at Memorial Regional Hospital in Hollywood, Florida. He is involved in many regional and national professional and scientific associations including The Endocrine Society and the American Diabetes Association and is Past President of The Florida Endocrine Society. Dr. Jellinger is board certified in internal medicine and endocrinology and metabolism. He has also conducted investigative research on over 50 subjects and is currently conducting research for several major pharmaceutical companies. Dr. Jellinger currently serves as Medical Editor of Clinical Endocrinology News.

Dr. Jellinger, a founding member, was elected President of the American Association of Clinical Endocrinologists, a 5500 physician member organization, in May 2000. He has been active on the AACE Board of Directors and has served as chairman of several committees including the Clinical Research Committee. Dr. Jellinger was also a member of the Task Forces that defined and published the first AACE Guidelines for the Management of Diabetes Mellitus the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism and the Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. He served as Chairman of the Task Force for the published AACE Guidelines on the Treatment of Lipid Disorders in the Prevention of Atherogenesis. He was a participant in both the 2001 and 2002 “ACE/AACE Consensus Conferences on Glycemic Control” and the “Insulin Resistance Syndrome” and was a co-chairman of the recent “ACE/AACE Diabetes Consensus Conference on Implementation of Glycemic Goals.” He is co-chairman of the Task Force that recently published the ACE/AACE Roadmap for the Treatment and Prevention of Type 2 Diabetes and was a Task Force member and contributing author to the recently published AACE Medical Guidelines for the Management of Diabetes Mellitus. Dr. Jellinger lectures frequently on topics related to diabetes mellitus and lipid disorders.

Laurence Katznelson, MD received his medical degree from the University of California, Los Angeles and performed his internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania, Philadelphia. He then performed a fellowship in endocrinology and metabolism at the Massachusetts General Hospital, Boston. Dr. Katznelson is an Associate Professor of Neurosurgery and Medicine at Stanford University School of Medicine. At Stanford University, he is the Program Director for the Endocrine fellowship training program. He is a member of the Editorial Boards for Pituitary and the Journal of Clinical Endocrinology and Metabolism. Dr. Katznelson is a member of the Special Programs Committee and the Clinical Affairs Core Committee of the Endocrine Society. He has served as an ad hoc member of NIH study sections. Dr. Katznelson is currently Chairman of Membership for the Pituitary Society. Dr. Katznelson has a long standing clinical and research interest in the pathophysiology and treatment of pituitary disease.

Philip Levy, MD, earned his BS with high honors at the University of Pittsburgh and his MD at the University of Pittsburgh School of Medicine, where he was a member of Alpha Omega alpha. He held a rotating internship followed by a fellowship in basic science at Michael Reese Hospital in Chicago, where he was also a resident and chief resident in internal medicine and a fellow in endocrinology and metabolism. He served as a clinical instructor in medicine at Chicago Medical School and as a research fellow with the American Diabetes Association at Guy's Hospital Medical School in London before opening a clinical practice in endocrinology in Phoenix, and he is a clinical professor of medicine at the University of Arizona College of Medicine.

Dr. Levy is the chairman of the section of endocrinology and metabolism at Good Samaritan Hospital and St. Joseph's Hospital, both in Phoenix. He is a past president of the Arizona Diabetes Association currently serves on the organization's board of directors. He has served on the board of directors and many committees of the American Diabetes Association, including the professional education committee and the governmental relations committee. A previous member of the board of directors of the American Association of Clinical Endocrinologists, Dr. Levy is a also a fellow of the American College of Endocrinology and a member of the Endocrine Society, the American College of Physicians, the American Diabetes Association, the Society of Nuclear Medicine, and the American Association of Clinical Endocrinologists. A frequently published author, Dr. Levy is on the editorial boards of Clinical Endocrinology and Endocrine Today.

Dr. Etie Moghissi is a member of the Board of Directors of the American Association of Clinical Endocrinologists (AACE) and the Immediate Past President of the California Chapter of the AACE. She is the co- chair of AACE Inpatients Diabetes Taskforce and serves as the co-chair of the American College of Endocrinology's (ACE) Consensus Development Conference on Inpatient Diabetes and Metabolic Control.

Board certified in internal medicine and endocrinology, Dr. Moghissi is in private practice in Inglewood, California, where she is the Medical Director of the Diabetes Care Center the Weight Management Program at Cantilena Freeman Health System in Inglewood and Marina Del-Ray, California

From 1990 to 2004 she held a position of Clinical Associate Professor of Medicine at the University of Southern California.

A graduate of Pahlavi University and Pahlavi University Medical School in Shiraz, Iran, Dr. Moghissi completed residency at both Namazee Hospital in Shiraz, Iran, and St. Luke's Roosevelt Hospital at Columbia University in NYC. She completed her fellowship in endocrinology at the University of Southern California.

A Charter Member of the AACE, she has served on several task forces, including the Endocrine Education for PCP, the In-Patient Diabetes Consensus Conference, and the Intensive Insulin Management Guidelines. Dr. Moghissi has participated in several AACE committees, including the Annual Meeting Clinical Congress Program Committee, Chapters Steering Committee, and the Nominating Committee.

Vijay Nambi is an Assistant Professor in the section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine and Center for Cardiovascular Prevention, the Methodist DeBakey Heart Center. He also serves as the program director of the Atherosclerosis and Vascular Medicine fellowship at Baylor College of Medicine. His research interests are specifically in lipids, biomarkers, risk stratification and imaging as related to coronary and peripheral arterial disease. He has published 20 original articles and 3 book chapters.

Eric A. Orzeck, MD, FACE, CDE, is a clinical associate professor in the section of endocrinology in the department of internal medicine at Baylor College of Medicine. He is also a member of the clinical faculty of the University of Texas Medical School.

Dr. Orzeck earned his MD from the University of Virginia Medical Centerand completed his post-graduate training at the University of Iowa Hospitals. He completed his first endocrine fellowship at the University of Virginia Medical Center. He completed his second fellowship at the University of Texas MD Anderson Hopsital and Tumor Institute, now the MD Anderson Cancer Center.

Dr. Orzeck is a certified diabetes educator, and he has been elected to the National Certification Board for Diabetes Educators. He has been published over 100 times on the subject of diabetes and currently serves on the editorial boards of Practical Diabetology and Diabetes Self-Management.
The professional societies and associations that Dr. Orzeck is a member of include the Houston Society of Clinical Endocrinology, where he served as president and the American Association of Clinical Endocrinologists, where he has been appointed to the coding committee, socioeconomic committee and nuclear medicine certifications board committee. Dr. Orzeck has also served as president of the Southeast Texas Chapter of the American Association of Diabetes Educators and the Houston Chapter of the American Diabetes Association.

He is currently Associate Editor, Hormone Research and in 2007 co-edited the 2nd edition of Growth Disorders.

His research interests are Turner Syndrome, growth and puberty disorders. He has published over 180 peer-reviewed original articles. He has trained more than 30 pediatric endocrinologists in the United States and Europe.

Addison A. Taylor, M.D., Ph.D., F.A.H.A., is a Professor of Medicine, Professor of Pharmacology, and Professor of Molecular Physiology and Biophysics, and is the Chief of the Section of Hypertension and Clinical Pharmacology in the Department of Medicine, Baylor College of Medicine. He has been a principal investigator or co-principal investigator in over 400 clinical trials investigating mechanisms and new therapies for hypertension and hypotension. He has authored or co-authored over 120 scientific publications, and has participated as an invited speaker at many national and international meetings.

In addition, Dr. Taylor serves as a consultant to the Cardiovascular and Renal Drug Advisory Committee of the Food and Drug Administration. Dr. Taylor is a Fellow of the American Heart Association and is a member of the Council for High Blood Pressure Research, the Council for Basic Cardiovascular Research, and the Council for Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association.

Dr. Taylor received his M.D. and Ph.D. degrees from the University of Missouri in Columbia. He also spent six years at the National Heart, Lung and Blood Institute of the National Institutes of Health in Maryland before joining the Baylor faculty in 1977.

Joseph J. Torre, M.D., F.A.C.P., F.A.C.E., is Clinical Assistant Professor of Medicine for the State University of New York at Buffalo where he has been in the private practice of endocrine consultation with the Buffalo Medical Group, P.C. since 1991. He served as chairman of the task force that developed the AACE Medical Guidelines for the Diagnosis and Management of Hypertension and as section editor of the Hypertension module of the AACE/ACE Self Assessment Program (ASAP) for 2007-2008. A graduate of the Boston University School of Medicine, his endocrinology career stemmed from an interest in the etiology of atherogenesis and research in platelet sensitivity and vascular reactivity associated with hyperlipidemia and diabetes mellitus at St. Luke’s Hospital Medical Center in NYC, NY, and later at the M.I.T. Arteriosclerosis Center in Cambridge, MA. Dr. Torre sees the clinical endocrinologist as the quintessential diagnostician and preventive medicine specialist. He credits AACE with helping to bring endocrinology from an esoteric subspecialty to the forefront of the clinical practice of internal medicine.